AnGes MG,Inc. AnGes MG,Inc. Japanese Site
Home News Releases About Us Projects For Investors
Print
  News Releases
  The latest news
  Back numbers
HOME > News Releases > The latest news
News Releases The latest news

The latest news keep you up-to-date on the developments
at AnGes MG, Inc..
Click here to read news releases.

Back numbers >>Back numbers
List(2006-2005)
2008  
May 26 Medical Use Patent for the Combination Use of HGF and PGIS Granted in Europe - Covering Angiogenic Therapy -
May 15 New Medical-Use Patent for HGF Gene Granted in Europe - Covering Cardiomyopathy -
April 14 AnGes MG, Inc. Launched Naglazyme in Japan
April 7 Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis
March 28 AnGes Submits NDA for HGF Gene Therapy
March 28 AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme
February 25 Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI
February 12 Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis
February 8 Announcement of Results of Phase II Clinical Trials of
NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis
2007  
December 10 Option Agreement Concluded Between Maruishi Pharmaceutical Co., Ltd. and AnGes MG, Inc. - Implementing Exploratory Research on Candidate Compound for Novel Drug for Treatment of Skin Diseases -
November 15 Announcement of a Contract Concluded by Three Companies on
R&D of “Drug-Eluting Balloon Catheter” for Prevention of
Vascular Restenosis
November 15 Announcement of Joint R&D Contract Termination between
Goodman Co., Ltd. and AnGes MG, Inc.
November 13 AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe-
October 29 Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan
August 31 A Research-and-Development Project of GenomIdea Inc.,a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector -
August 29 Basic Patent of HGF Gene Therapy is Granted in Korea
August 13 AnGes MG, Inc. Submits BLA for Naglazyme in Japan
July 11 Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent)
July 9 Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan
June 20 Announcement on Acquisition of First-Class Drug Marketing Business License
June 14 Announcement of Results of Phase III Clinical Trials of HGF Gene Therapy in Japan
June 7 Announcement Regarding the Official Designation of Naglazyme as an Orphan Drug
February 15 Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing -
February 7 New Medical-Use Patent for HGF Gene Granted in Japan - Covering Intractable and Diabetes-related Peripheral Arterial Occlusive Diseases -
January 22 AnGes MG, Inc. Announces Marketing and Distribution Agreement with BioMarin Pharmaceutical Inc. for Naglazyme in Japan
January 11 The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary
Number of Subject Enrollment for Efficacy Analysis
January 10 New Medical-Use Patent for HGF Gene Granted in Japan - Covering Cardiomyopathy -
January 5 Vical Initiates Pivotal Phase 3 Trial of Allovectin-7® as First-line Therapy for Metastatic Melanoma
2006  
November 13 Avontec (Germany) Starts Phase IIa Clinical Trials of AVT-01
- Obtaining Approval for Initiation of Clinical Trials in the Field of Asthma in Europe -
October 31 AnGes MG Launches Phase II Clinical Trials of NF-κB Decoy Oligo in the Treatment of Atopic Dermatitis in Japan
October 18 Efficacy of Drug Delivery System (DDS) Nanoparticles Supported Nucleic Acid Medicine for Atopic Dermatitis, Developed by Hosokawa Powder Technology Research Institute and AnGes MG, Inc. Confirmed in Animal Experiments
September 7 AnGes MG Submitted the Notification of the Clinical Trial Plan for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis Commences -
June 5 AnGes MG, Inc. Announce their Policy for Future Development of HGF Gene Therapy
June 5 AnGes MG, Inc. Releases the Results of the US Phase II
Clinical Trial with HGF Gene Plasmid for PAD (Peripheral Arterial Disease)
June 1 Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent-
May 30 AnGes MG, Inc. and Vical Inc. Sign Collaborative R&D Agreement for Allovectin-7® as well as Equity Investment Agreement
May 26 Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis
May 24 A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis-
May 8 Results of the US Phase I Clinical Trials with HGF Gene Plasmid for Ischemic Heart Disease (IHD)
April 3 AnGes MG, Inc. Announces Newly Establishing a Position of CIPO(Chief Intellectual Property Officer)
February 22 AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease)
February 3 Termination of Joint Development with Seikagaku Corporation
January 31 Medical-Use Patent for HGF Gene Granted in U.S.
- Covering Cardiomyopathy -

Back numbers Page Top


Copyright 2004 AnGes MG All rights reserved. Contact | Site Map | Site Policy | Privacy Policy